With many PBMs receiving scrutiny, smaller startups that bill themselves as more transparent are seeing interest from employers in the state and nationally.

In 2014, Caremark was accused of manipulating how drug costs were reported, prompting Aetna and SilverScript to submit false ...

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gov. Ned Lamont signed Public Act 25-167 into law July 30. Its aim is to implement the task force’s recommendations in an ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...